No Data
No Data
No Data
No Data
No Data
HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Lowers Price Target to $16
HC Wainwright & Co. analyst Joseph Pantginis maintains Astria Therapeutics with a Buy and lowers the price target from $18 to $16.
Analyst UpgradesApr 23 18:22
In the Wake of Astria Therapeutics, Inc.'s (NASDAQ:ATXS) Latest US$51m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions
Key Insights Given the large stake in the stock by institutions, Astria Therapeutics' stock price might be vulnerable to their trading decisions 52% of the business is held by the top 7 shareholders
Simply Wall StApr 11 22:28
Astria Therapeutics Appoints Sunil Agarwal to Its Bd of Directors
Astria Therapeutics Appoints Sunil Agarwal to Its Bd of Directors
Dow JonesApr 9 20:01
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)
Yahoo FinanceApr 4 07:00
Astria Therapeutics Inc(ATXS.US) Officer Sells US$135.94K in Common Stock
$Astria Therapeutics Inc(ATXS.US)$ Officer Morabito Christopher sold 10,000 shares of Common Stock on Apr 1, 2024 at an average price of $13.5939 for a total value of $135.94K.Source: Announcement Wha
Futu NewsApr 4 04:47
Form 144 | Astria Therapeutics Inc(ATXS.US) Officer Proposes to Sell 135.94K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 1, $Astria Therapeutics Inc(ATXS.US)$ Officer CHRIS MORABITO intends to sell 10,000 shares of its common stock on Apr 1, with a total market value of approximately $135.94K
Futu NewsApr 2 05:13
No Data
No Data